Antibodies
6 March 2013
Roche obtains EU approval for PERJETA, a new personalised treatment for aggressive type of breast cancer25 February 2013
Avaxia Biologics Announces First Patient Dosed in Phase 1b Study of AVX-470 in Ulcerative Colitis25 February 2013
Dyax Presents DX-2930 Data at the 2013 American Academy of Allergy, Asthma and Immunology Annual Meeting25 February 2013
Novartis reports Phase III data showing omalizumab improved itch in patients with a chronic form of hives who failed standard therapy24 February 2013
FDA approves Roche’s Kadcyla (trastuzumab emtansine), the first antibody-drug conjugate for treating HER2-positive metastatic breast cancer20 February 2013
UCB Announces Regulatory Filings for Cimzia® (Certolizumab Pegol) to Treat Psoriatic Arthritis and Axial Spondyloarthritis20 February 2013
Thallion and LFB Terminate Shigamabs Collaboration19 February 2013
Regeneron and Bayer Initiate Phase 3 Trial of EYLEA (aflibercept) Injection for the Treatment of Diabetic Macular Edema in Asia and Russia19 February 2013
Peregrine Pharmaceuticals Updates Top-Line Data From Phase II Clinical Trial of Bavituximab in Second-Line Non-Small Cell Lung Cancer13 February 2013
Peregrine Pharmaceuticals Announces Results From Phase II Clinical Trial of Bavituximab in Stage IV Pancreatic CancerNews Channels
Newsletter
La Merie Biologics
La Merie Publishing releases a weekly newsletter with a focus on biopharmaceutical research and development.
Subscribe
Newsletter
New Product Alert
La Merie Publishing offers an e-mail notification service about the release of new products of La Merie Publishing. This New Product Release Alert also informs about the release of FREE reports produced by La Merie Publishing.
Subscribe
Featured reports